ORIGIMM Biotechnology Initiates First-in-Human Trial of Acne Vulgaris Vaccine

We are proud to announce the start of First-In-Human clinical trial of acne vulgaris vaccine, which is the major milestone for Origimm in bringing to clinical trial a world-wide first vaccine candidate against the bacteria involved in pathogenesis of acne.

The Phase I/IIa study will evaluate the safety and immunogenicity of the Origimm vaccine in acne patients, a possible breakthrough therapy for acne vulgaris. Relentless and dedicated efforts brought us to this point, and we are very grateful to our whole team for making this happen!

Origimm Clinical Trial_Homepage Press Release